Masimo Corp

Masimo operates with a capital structure that includes $524.3 million in long-term debt and $152.3 million in cash and equivalents, resulting in a debt-to-equity ratio of 0.73 and a current ratio of 2.49. The company's liquidity position is assessed as medium risk, with net cash negative after subtracting total debt. Free cash flow of $221.8 million supports operational flexibility, but the price-to-book ratio of 12.96 suggests a premium valuation relative to tangible assets. Profitability metrics show mixed performance. Gross profit of $946.7 million represents 62% of revenue, but net income is negative at -$151.5 million, leading to a return on equity of -21.01% and return on assets of -8.92%. These figures fall below the industry median for ROE and ROA in the Medical Equipment, Supplies & Distribution sector, indicating underperformance in capital efficiency and cost control. Geographically, Masimo's revenue is concentrated in the United States, with no disclosed international segments in the latest financials. The company's product portfolio is centered on core monitoring technologies, with limited diversification into new therapeutic or diagnostic applications. Revenue growth has slowed in recent periods, with a trailing twelve-month revenue of $1.53 billion. Outlook for the current fiscal year shows a modest increase in revenue, but the net income remains negative. The company's operating income of $310 million is a positive sign, but insufficient to offset losses from other operations. Risk factors include liquidity constraints and the potential for dilution, though the latter is currently assessed as low. The company has not issued additional shares in the past year, and no dilutive events are disclosed in recent filings. However, the negative net income and high price-to-book ratio suggest valuation risks. Recent events include a 10-K filing disclosing ongoing R&D investments in new monitoring technologies and a 10-Q update on supply chain challenges. No major regulatory or litigation events were reported in the latest filings, but the company faces competitive pressures in the non-invasive monitoring market.